Related Experiment Video

Updated: Aug 11, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.2K

Biologics for pediatric atopic dermatitis: A protocol of a systematic review and meta-analysis

Rui Cao1, Jiaxing Lu1, Zhao Chen2

  • 1North China University of Science and Technology, Hebei, Tangshan, China.

Plos One
|February 3, 2023
PubMed

Insights

This systematic review evaluates biologic treatments for pediatric atopic dermatitis (AD). It synthesizes evidence on efficacy and safety, offering clinical guidance for this common childhood skin condition.

Area of Science:

  • Dermatology
  • Pediatrics
  • Immunology

Background:

  • Atopic dermatitis (AD) is a chronic, itchy inflammatory skin condition prevalent in children.
  • Biologic therapies have shown promising results in recent clinical trials for AD treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of biologic agents in treating pediatric atopic dermatitis (AD).
  • To provide evidence-based data for the clinical application of biologics in children with AD.

Main Methods:

  • Extensive search of RCTs in Embase, Cochrane Library, Web of Science, and PubMed until May 15, 2022.
  • Primary outcomes: EASI 75/90/100 at 12-16 weeks. Secondary outcomes: NRS, IGA, BSA, DLQI, and adverse events.
  • Risk of bias assessment using Cochrane System Review Manual 5.1.0; meta-analysis using RevMan V.5.3.0.

Main Results:

  • The research results will provide a reference for the clinical application of biological agents in pediatric atopic dermatitis.

Conclusions:

  • The study aims to evaluate the efficacy and safety of biologics in pediatric atopic dermatitis.
  • Evidence-based data will be provided for easier clinical application.
Abstract

More Related Videos

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

876
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
205
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
155
Allergic Reactions02:06

Allergic Reactions

Overview
28.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
229
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169